We are live on ! Find out more
TRIB

Trinity Biotech

26 hedge funds and large institutions have $2.59M invested in Trinity Biotech in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

30% more funds holding

Funds holding: 2026 (+6)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.01% less ownership

Funds ownership: 0.8%0.79% (-0.01%)

42% less capital invested

Capital invested by funds: $4.49M → $2.59M (-$1.9M)

83% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 6

Holders
26
Holders Change
+6
Holders Change %
+30%
% of All Funds
0.38%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
7
Increased
1
Reduced
6
Closed
1
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Group One Trading
26
Group One Trading
Illinois
-$12.2K -3,338 Closed
Simplex Trading
27
Simplex Trading
Illinois
+$234 +98 New

TRIB Hedge Fund Activity: Q4 2023 in Review

26 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q4 2023, worth a combined $2.59M — down 42% from $4.49M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new TRIB positions and 1 closed out — a net gain of 6 holders — while 1 added to existing stakes and 6 trimmed.

The largest buyer was Becker Capital Management, opening a new position worth an estimated $43K. The largest seller was Aristides Capital, cutting an estimated $64.1K.

  • 26 institutional investors held Trinity Biotech (TRIB) as of Q4 2023, up from 20 in Q3 2023.
  • Funds reported $2.59M of Trinity Biotech stock for Q4 2023, down 42% quarter-over-quarter.
  • 7 funds opened new Trinity Biotech positions in Q4 2023 and 1 closed out, a net change of +6 holders.
  • The largest Trinity Biotech buyer in Q4 2023 was Becker Capital Management, an estimated $43K added.
  • The largest Trinity Biotech seller in Q4 2023 was Aristides Capital, an estimated $64.1K sold.

Based on aggregated 13F filings for Q4 2023.